PP
AVDL

Paloma Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Paloma Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-22,970
Closed -$59K – 1679
2018
Q4 		$59K Buy
+22,970
New +$78.1K ﹤0.01% 1154

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Paloma Partners's AVDL Position: Q1 2019 in Review

Paloma Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2019, closing a stake of 22,970 shares — an estimated $59K sold.

Paloma Partners first reported a position in AVDL in Q4 2018 and held it in 1 quarter. The position peaked at $59K in Q4 2018. 49 funds tracked by Wall St. Rank hold AVDL as of Q1 2019.

  • Paloma Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Paloma Partners sold 22,970 Avadel Pharmaceuticals shares in Q1 2019, an estimated $59K.
  • Paloma Partners first reported a position in Avadel Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Paloma Partners's Avadel Pharmaceuticals position peaked at $59K in Q4 2018.
  • 49 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.